Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frits van Rhee

Showing results (71-80 of 274) with videos related to

Pageof 28
Sort By:
Ejhaem|August 19, 2024
Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamabSyed Naqvi, Asis Shrestha, Marah Alzubi, et al.
British Journal of Haematology|December 11, 2019
Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcomeMeera Mohan, Niels Weinhold, Carolina Schinke, et al.
British Journal of Haematology|April 7, 2009
Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profileYiming Zhou, Bijay Nair, John D Shaughnessy, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|February 13, 2014
A compound T60A and V122I heterozygosity in the transthyretin gene causing early onset severe cardiac amyloidosisYi-Chang Liu, Honey Vodur Reddi, Sarah Waheed, et al.
British Journal of Haematology|February 28, 2008
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2Mauricio Pineda-Roman, Maurizio Zangari, Jeff Haessler, et al.
Blood Advances|March 1, 2023
Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysisFarah Mazahreh, Liyan Mazahreh, Carolina Schinke, et al.
Frontiers in Immunology|August 5, 2022
Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modellingJean-François Rossi, Hao-Chun Chiang, Zhao-Yang Lu, et al.
Clinical Lymphoma & Myeloma|June 27, 2006
Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myelomaBart Barlogie, Maurizio Zangari, Vanessa Bolejack, et al.
British Journal of Haematology|July 6, 2018
Infectious and immunological sequelae of daratumumab in multiple myelomaAndrew J Johnsrud, Joyce J Johnsrud, Sandra A Susanibar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioningAshraf Badros, Bart Barlogie, Eric Siegel, et al.
Pageof 28

Showing results (71-80 of 274) with videos related to

Sort By:
Pageof 28
Ejhaem|August 19, 2024
Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamabSyed Naqvi, Asis Shrestha, Marah Alzubi, et al.
British Journal of Haematology|December 11, 2019
Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcomeMeera Mohan, Niels Weinhold, Carolina Schinke, et al.
British Journal of Haematology|April 7, 2009
Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profileYiming Zhou, Bijay Nair, John D Shaughnessy, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|February 13, 2014
A compound T60A and V122I heterozygosity in the transthyretin gene causing early onset severe cardiac amyloidosisYi-Chang Liu, Honey Vodur Reddi, Sarah Waheed, et al.
British Journal of Haematology|February 28, 2008
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2Mauricio Pineda-Roman, Maurizio Zangari, Jeff Haessler, et al.
Blood Advances|March 1, 2023
Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysisFarah Mazahreh, Liyan Mazahreh, Carolina Schinke, et al.
Frontiers in Immunology|August 5, 2022
Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modellingJean-François Rossi, Hao-Chun Chiang, Zhao-Yang Lu, et al.
Clinical Lymphoma & Myeloma|June 27, 2006
Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myelomaBart Barlogie, Maurizio Zangari, Vanessa Bolejack, et al.
British Journal of Haematology|July 6, 2018
Infectious and immunological sequelae of daratumumab in multiple myelomaAndrew J Johnsrud, Joyce J Johnsrud, Sandra A Susanibar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioningAshraf Badros, Bart Barlogie, Eric Siegel, et al.
Pageof 28